{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:27:29Z","timestamp":1788362849159,"version":"build-2803163510"},"reference-count":136,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1261,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1111\/j.1600-0404.2012.01661.x","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T06:39:05Z","timestamp":1332139145000},"page":"77-97","source":"Crossref","is-referenced-by-count":30,"title":["Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy"],"prefix":"10.1155","volume":"126","author":[{"given":"A.","family":"Bersano","sequence":"first","affiliation":[{"name":"Department of Emergency Neurology; IRCCS C. Mondino National Institute of Neurology Foundation; Pavia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lanfranconi","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences; Dino Ferrari Centre; IRCCS Ospedale Maggiore, Policlinico Mangiagalli and Regina Elena Foundation; University of Milan; Milan; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Valcarenghi","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences; Dino Ferrari Centre; IRCCS Ospedale Maggiore, Policlinico Mangiagalli and Regina Elena Foundation; University of Milan; Milan; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bresolin","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences; Dino Ferrari Centre; IRCCS Ospedale Maggiore, Policlinico Mangiagalli and Regina Elena Foundation; University of Milan; Milan; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Micieli","sequence":"additional","affiliation":[{"name":"Department of Emergency Neurology; IRCCS C. Mondino National Institute of Neurology Foundation; Pavia; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences; Dino Ferrari Centre; IRCCS Ospedale Maggiore, Policlinico Mangiagalli and Regina Elena Foundation; University of Milan; Milan; Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2012,3,19]]},"reference":[{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0001|ane1661-cit-0001","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1093\/clinchem\/13.7.565","article-title":"Enzymatic abnormalities in diseases of sphingolipid metabolism","volume":"13","author":"Brady","year":"1967","journal-title":"Clin Chem"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0002|ane1661-cit-0002","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry disease ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0003|ane1661-cit-0003","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1097\/01.ASN.0000015236.70757.C4","article-title":"Biochemical and molecular genetic basis of Fabry disease","volume":"13","author":"Pastores","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0004|ane1661-cit-0004","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"Sch\u00e4fer","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0005|ane1661-cit-0005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0006|ane1661-cit-0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000060195","article-title":"Neurological manifestation of Fabry disease in females","volume":"136","author":"Wendrich","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0007|ane1661-cit-0007","first-page":"440","article-title":"Fabry disease-often seen, rarely diagnosed","volume":"106","author":"Hoffmann","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0008|ane1661-cit-0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0009|ane1661-cit-0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0010|ane1661-cit-0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0011|ane1661-cit-0011","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0012|ane1661-cit-0012","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","article-title":"Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients","volume":"41","author":"Baptista","year":"2010","journal-title":"Stroke"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0013|ane1661-cit-0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/STROKEAHA.109.558320","article-title":"Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke","volume":"41","author":"Wozniak","year":"2010","journal-title":"Stroke"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0014|ane1661-cit-0014","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0015|ane1661-cit-0015","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0016|ane1661-cit-0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00868342","article-title":"Stroke in Fabry disease","volume":"241","author":"Grewal","year":"1994","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0017|ane1661-cit-0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/08035320510028076","article-title":"Natural history of the cerebrovascular complications of Fabry disease","volume":"94","author":"Mehta","year":"2005","journal-title":"Acta Paediatr"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0018|ane1661-cit-0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0019|ane1661-cit-0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0020|ane1661-cit-0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.ASN.0000015239.57436.18","article-title":"Anderson-Fabry disease: extrarenal, neurologic manifestations","volume":"13","author":"Kolodny","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0021|ane1661-cit-0021","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","article-title":"Quantitative analysis of cerebral vasculopathy in patients with Fabry disease","volume":"50","author":"Crutchfield","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0022|ane1661-cit-0022","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000322153","article-title":"Protocol and methodology of the Stroke in Young Fabry Patients (sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18-55\u00a0years","volume":"31","author":"Rolfs","year":"2011","journal-title":"Cerebrovasc Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0023|ane1661-cit-0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ana.21196","article-title":"Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children","volume":"62","author":"Uusimaa","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0024|ane1661-cit-0024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1196\/annals.1444.011","article-title":"Mitochondrial encephalopathy, lactic acidosis, and stroke like episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome","volume":"1142","author":"Sproule","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0025|ane1661-cit-0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1212\/01.wnl.0000180965.79209.50","article-title":"Large cerebral artery involvement in CADASIL","volume":"65","author":"Choi","year":"2005","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0026|ane1661-cit-0026","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1212\/01.wnl.0000246601.70918.06","article-title":"Intracerebral hemorrhages in CADASIL","volume":"67","author":"Choi","year":"2006","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0027|ane1661-cit-0027","unstructured":"Schermuly I M\u00fcller MJ Keller I Neuropsychiatric symptoms, disease burden and brain structure in Fabry disease 2008"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0028|ane1661-cit-0028","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1474-4422(09)70127-9","article-title":"Cadasil","volume":"8","author":"Chabriat","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0029|ane1661-cit-0029","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00415-009-5191-6","article-title":"Nerve conduction studies in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy","volume":"256","author":"Kang","year":"2009","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0030|ane1661-cit-0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0161-6420(88)33131-3","article-title":"Cerebroretinal vasculopathy","volume":"95","author":"Grand","year":"1988","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0031|ane1661-cit-0031","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/WNL.49.5.1322","article-title":"Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS)","volume":"49","author":"Jen","year":"1997","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0032|ane1661-cit-0032","first-page":"78","article-title":"Fabry disease without cutaneous angiokeratoma: diagnosis by electron microscope study of skin biopsy","volume":"57","author":"Le Charpentier","year":"1981","journal-title":"Sem Hop"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0033|ane1661-cit-0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000073054","article-title":"Microembolus detection in four patients with Fabry disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms","volume":"50","author":"Ritter","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0034|ane1661-cit-0034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archneurol.2009.309","article-title":"Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes","volume":"67","author":"Testai","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0035|ane1661-cit-0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0036|ane1661-cit-0036","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0037|ane1661-cit-0037","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis","volume":"14","author":"Eitzman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0038|ane1661-cit-0038","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1681\/ASN.2005040383","article-title":"An in vitro model of Fabry disease","volume":"16","author":"Shu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0039|ane1661-cit-0039","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.STR.0000206442.86238.39","article-title":"Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation","volume":"37","author":"Shen","year":"2006","journal-title":"Stroke"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0040|ane1661-cit-0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2169\/internalmedicine.36.327","article-title":"High incidence of thrombosis in Fabry disease","volume":"36","author":"Utsumi","year":"1996","journal-title":"Intern Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0041|ane1661-cit-0041","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/08035320600618932","article-title":"Fabry disease and vascular risk factors: future strategies for patient-based studies and the knockout murine model","volume":"95","author":"Moore","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0042|ane1661-cit-0042","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1681.2008.04984.x","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","volume":"35","author":"Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0043|ane1661-cit-0043","first-page":"295","article-title":"Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease","volume":"24","author":"Puccio","year":"2005","journal-title":"Int Angiol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0044|ane1661-cit-0044","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-006-0340-x","article-title":"Structural and functional changes in peripheral vasculature of Fabry patients","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0045|ane1661-cit-0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0046|ane1661-cit-0046","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0047|ane1661-cit-0047","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10545-006-0473-y","article-title":"Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease, partial prevention by N-butyldeoxynojirimycin treatment","volume":"30","author":"Heare","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0048|ane1661-cit-0048","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","article-title":"Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency","volume":"111","author":"Bodary","year":"2005","journal-title":"Circulation"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0049|ane1661-cit-0049","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","article-title":"Endothelial markers and homocysteine in patients with classic Fabry disease","volume":"91","author":"Demuth","year":"2002","journal-title":"Acta Paediatr Suppl"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0050|ane1661-cit-0050","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/brain\/awh546","article-title":"Megadolichobasilar anomaly with thrombosis in a family with Fabry disease and a novel mutation in the alpha-galactosidase A gene","volume":"128","author":"Garzuly","year":"2005","journal-title":"Brain"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0051|ane1661-cit-0051","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2009.02.319","article-title":"Thrombosis in Japanese patients with Fabry disease","volume":"283","author":"Utsumi","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0052|ane1661-cit-0052","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/01.wnl.0000338566.54190.8a","article-title":"Diagnostic utility of different MRI and MR angiography measures in Fabry disease","volume":"72","author":"Fellgiebel","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0053|ane1661-cit-0053","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0054|ane1661-cit-0054","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease","volume":"251","author":"Hilz","year":"2004","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0055|ane1661-cit-0055","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0056|ane1661-cit-0056","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","article-title":"CNS manifestations of Fabry disease","volume":"5","author":"Fellgiebel","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0057|ane1661-cit-0057","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","article-title":"CNS involvement in Fabry disease: clinical and imaging studies before and after 12\u00a0months of enzyme replacement therapy","volume":"27","author":"Jardim","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0058|ane1661-cit-0058","first-page":"1096","article-title":"Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease","volume":"24","author":"Moore","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0059|ane1661-cit-0059","first-page":"916","article-title":"T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease","volume":"24","author":"Takanashi","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0060|ane1661-cit-0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/A:1012499119196","article-title":"Natural history of Fabry disease in males: preliminary observations","volume":"24","author":"Schiffmann","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0061|ane1661-cit-0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archneur.1970.00480190085014","article-title":"Peripheral nerve involvement in Fabry's disease","volume":"22","author":"Kocen","year":"1970","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0062|ane1661-cit-0062","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0063|ane1661-cit-0063","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1085-9489.2006.00076.x","article-title":"Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin","volume":"11","author":"Moller","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0064|ane1661-cit-0064","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/art.1780220715","article-title":"The arthropathy of Fabry disease","volume":"22","author":"Sheth","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0065|ane1661-cit-0065","first-page":"366","article-title":"Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis)","volume":"74","author":"Rahman","year":"1971","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0066|ane1661-cit-0066","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000060196","article-title":"Clinical manifestation in female Fabry disease patients","volume":"136","author":"Whybra","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0067|ane1661-cit-0067","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2190\/JKFW-3WXK-QA7N-BYLN","article-title":"Psychiatric disorders in patients with Fabry disease","volume":"23","author":"Grewal","year":"1993","journal-title":"Int J Psychiatry Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0068|ane1661-cit-0068","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","article-title":"Small fiber dysfunction predominates in Fabry neuropathy","volume":"19","author":"D\u00fctsch","year":"2003","journal-title":"J Clin Neurophysiol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0069|ane1661-cit-0069","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","article-title":"Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients","volume":"84","author":"Hilz","year":"2000","journal-title":"Pain"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0070|ane1661-cit-0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","article-title":"Physiological characterization of neuropathy in Fabry disease","volume":"26","author":"Luciano","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0071|ane1661-cit-0071","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archneur.1974.00490380068009","article-title":"Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns","volume":"31","author":"Onishi","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0072|ane1661-cit-0072","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s004150050125","article-title":"Nerve biopsy findings in hemizygous and heterozygous patients with Fabry's disease","volume":"244","author":"Toyooka","year":"1997","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0073|ane1661-cit-0073","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","article-title":"Involvement of dorsal root ganglia in Fabry disease","volume":"20","author":"Gadoth","year":"1983","journal-title":"J Med Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0074|ane1661-cit-0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0404.1999.tb07386.x","article-title":"Mechanisms of pain in peripheral neuropathy","volume":"173","author":"Attal","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0075|ane1661-cit-0075","first-page":"61","article-title":"Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy","volume":"106","author":"Schiffmann","year":"2006","journal-title":"Acta Neurol Belg"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0076|ane1661-cit-0076","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1179\/016164101101199414","article-title":"Gabapentin: a unique anti-epileptic agent","volume":"23","author":"Dougherty","year":"2001","journal-title":"Neurol Res"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0077|ane1661-cit-0077","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","article-title":"Carbamazepine in Fabry disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction","volume":"39","author":"Filling-Katz","year":"1989","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0078|ane1661-cit-0078","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(05)74815-7","article-title":"Autonomic peripheral neuropathy","volume":"365","author":"Freeman","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0079|ane1661-cit-0079","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s004150170109","article-title":"Hereditary and acquired amyloid neuropathies","volume":"248","author":"Adams","year":"2001","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0080|ane1661-cit-0080","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/brain\/awf270","article-title":"Clinical and genetic characterization of families with triple A (Allgrove) syndrome","volume":"125","author":"Houlden","year":"2002","journal-title":"Brain"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0081|ane1661-cit-0081","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1212\/WNL.31.4.461","article-title":"The splanchnic autonomic outflow in amyloid neuropathy and Tangier disease","volume":"31","author":"Low","year":"1981","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0082|ane1661-cit-0082","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/01.wnl.0000327870.29639.20","article-title":"Severe Tangier disease with a novel ABCA1 gene mutation","volume":"71","author":"Schippling","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0083|ane1661-cit-0083","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ana.410060404","article-title":"Multiple endocrine neoplasia, type 2b: phenotype recognition, neurological features and their pathological basis","volume":"6","author":"Dyck","year":"1979","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0084|ane1661-cit-0084","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1212\/WNL.43.6.1120","article-title":"Familial sensory autonomic neuropathy with arthropathy in Navajo children","volume":"43","author":"Johnsen","year":"1993","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0085|ane1661-cit-0085","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","article-title":"Fabry disease: impaired autonomic function","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0086|ane1661-cit-0086","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0087|ane1661-cit-0087","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/1086508X.1999.11079251","article-title":"The autonomic laboratory","volume":"39","author":"Low","year":"1999","journal-title":"Am J Electroneurodiagnostic Technol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0088|ane1661-cit-0088","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02291231","article-title":"Possible mechanism of anydrosis in a symptomatic female carrier of Fabry disease: an assessment by skin sympathetic nerve activity and sympathetic skin response","volume":"6","author":"Yamamoto","year":"1996","journal-title":"Clin Auton Res"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0089|ane1661-cit-0089","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000047393","article-title":"Unexpected diagnosis of Fabry disease in an 80-year-old man with syncope","volume":"96","author":"Lien","year":"2001","journal-title":"Cardiology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0090|ane1661-cit-0090","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00415-007-0575-y","article-title":"Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy","volume":"254","author":"Palla","year":"2007","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0091|ane1661-cit-0091","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0092|ane1661-cit-0092","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0093|ane1661-cit-0093","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakurab","year":"2006","journal-title":"J Hum Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0094|ane1661-cit-0094","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/GIM.0b013e3181f6e676","article-title":"Therapeutic goals in the treatment of Fabry disease","volume":"12","author":"Mehta","year":"2010","journal-title":"Genet Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0095|ane1661-cit-0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0096|ane1661-cit-0096","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0097|ane1661-cit-0097","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"Imbriaco","year":"2009","journal-title":"Heart"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0098|ane1661-cit-0098","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0099|ane1661-cit-0099","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1023\/A:1012451320105","article-title":"Enzyme replacement therapy in Fabry disease","volume":"24","author":"Brady","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0100|ane1661-cit-0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0101|ane1661-cit-0101","first-page":"69","article-title":"Enzyme replacement therapy for Fabry disease: some answers but more questions","volume":"7","author":"Alphadel","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0102|ane1661-cit-0102","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0103|ane1661-cit-0103","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","article-title":"Prevalence of uncontrolled hypertension in patients with Fabry disease","volume":"19","author":"Kleinert","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0104|ane1661-cit-0104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0105|ane1661-cit-0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0106|ane1661-cit-0106","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study","volume":"79","author":"Buechner","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0107|ane1661-cit-0107","volume-title":"Fabry disease: perspectives from 5\u00a0years of FOS","author":"Schiffmann","year":"2006"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0108|ane1661-cit-0108","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-009-0211-y","article-title":"Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy","volume":"31","author":"Salviati","year":"2010","journal-title":"Neurol Sci"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0109|ane1661-cit-0109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0110|ane1661-cit-0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0111|ane1661-cit-0111","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0112|ane1661-cit-0112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0113|ane1661-cit-0113","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0114|ane1661-cit-0114","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BOLI.0000028726.11177.8b","article-title":"Clinical benefit in Fabry patients given enzyme replacement therapy-a case series","volume":"27","author":"Guffon","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0115|ane1661-cit-0115","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0116|ane1661-cit-0116","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0117|ane1661-cit-0117","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0118|ane1661-cit-0118","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J Med Genet"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0119|ane1661-cit-0119","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0120|ane1661-cit-0120","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0121|ane1661-cit-0121","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u00a0mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0122|ane1661-cit-0122","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0123|ane1661-cit-0123","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0124|ane1661-cit-0124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CRD.0b013e31818adc50","article-title":"Fabry disease: cardiac manifestations and therapeutic options","volume":"17","author":"Pierre-Louis","year":"2009","journal-title":"Cardiol Rev"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0125|ane1661-cit-0125","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0149-2918(08)80037-9","article-title":"Fabry disease- whom to treat and when","volume":"30","author":"Mehta","year":"2008","journal-title":"Clin Ther"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0126|ane1661-cit-0126","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0127|ane1661-cit-0127","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1073\/pnas.051634498","article-title":"Adeno-associated viral vectormediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice","volume":"98","author":"Jung","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0128|ane1661-cit-0128","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0129|ane1661-cit-0129","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0537900100","article-title":"Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer","volume":"1006","author":"Park","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0130|ane1661-cit-0130","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking competent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0131|ane1661-cit-0131","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0132|ane1661-cit-0132","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10545-009-1156-2","article-title":"Can we use statins to prevent stroke in Fabry disease?","volume":"32","author":"Politei","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0133|ane1661-cit-0133","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","article-title":"Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction","volume":"39","author":"Filling-Katz","year":"1989","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0134|ane1661-cit-0134","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025127723729","article-title":"Use of gabapentin to reduce chronic neuropathic pain in Fabry disease","volume":"26","author":"Ries","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0135|ane1661-cit-0135","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"key":"10.1111\/j.1600-0404.2012.01661.x-BIB1661-bib-0136|ane1661-cit-0136","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/S0248-8663(10)70021-7","article-title":"Neurological complications in Fabry disease","volume":"31","author":"D\u00fctsch","year":"2010","journal-title":"Rev Med Interne"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2012.01661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2012.01661.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:50:20Z","timestamp":1671540620000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2012.01661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,19]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2012.01661.x","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3,19]]}}}